Response to "Successful treatment of refractory extensive pityriasis rubra pilaris with risankizumab"

Br J Dermatol. 2021 Mar 17. doi: 10.1111/bjd.20061. Online ahead of print.ABSTRACTWe read with great interest the article of J. Ricar and P. Cetkovska1 and congratulate the authors for the excellent outcome achieved. We would like, however, to add our personal opposing experience with the use of Risankizumab in the treatment of Pityriasis Rubra Pilaris (PRP).PMID:33730424 | DOI:10.1111/bjd.20061

Source: The British Journal of Dermatology - March 17, 2021 Category: Dermatology Authors: B Duarte M J Paiva Lopes Source Type: research